Although the incidence of cardiovascular events is directly related with the level of blood pressure, 1 the propensity of hypertensive patients to develop organ damage is under the influence of coexisting risk factors such as diabetes, dyslipidemia, smoking, and obesity. In addition to these classic risk factors, other systems contribute to the atherosclerotic process and may affect the impact of hypertension on the occurrence of cardiovascular events. Landmark studies 2, 3 demonstrated that an activated renin-angiotensin-aldosterone system (RAAS) is associated with an increased risk of coronary and cerebrovascular events independent of blood pressure levels and substantial evidence has subsequently linked pharmacological inhibition of the RAAS with effective cardiovascular 4 and renal 5 protection in hypertensive patients. In addition to its pressor effects, the RAAS has been associated with a variety of nonhemodynamic actions that might contribute to the progression of cardiovascular and renal pathology. 6 Many clinically relevant cardiovascular events in hypertensive patients are usually due to formation of a thrombus at the site of an atherosclerotic plaque. 7 Moreover, the hemostatic system is directly involved in the atherosclerotic process 8 and a prothrombotic state affects the impact of hypertension on the development of organ damage 9 and thereby on cardiovascular morbidity. 10, 11 Strong evidence that has been obtained both in animal and human studies supports an interaction between the RAAS and the coagulation and fibrinolytic systems (reviewed in ref. [12] [13] [14] . In hypertension, the link between the RAAS and the coagulation-fibrinolytic system is indirectly supported by the findings of a series of elegant studies conducted with RAAS blockers. [15] [16] [17] [18] [19] [20] [21] [22] We have hypothesized that an increased activity of the RAAS is associated with a prothrombotic state and thereby contribute to the development of organ damage in essential hypertension. To test this hypothesis, we have measured components of the RAAS and parameters that directly assess the activation of coagulation and fibrinolysis in a large group of hypertensive patients in whom the extent of organ damage has been characterized. Background components of the renin-angiotensin-aldosterone system (RAAS) and a prothrombotic state are predictors of cardiovascular events in hypertensive patients. A relationship between the RAAS and the coagulation/fibrinolytic systems has been demonstrated, but its clinical relevance in hypertension is unclear. We investigated the relationships of the RAAS and the hemostatic system with hypertensive organ damage.
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Although the incidence of cardiovascular events is directly related with the level of blood pressure, 1 the propensity of hypertensive patients to develop organ damage is under the influence of coexisting risk factors such as diabetes, dyslipidemia, smoking, and obesity. In addition to these classic risk factors, other systems contribute to the atherosclerotic process and may affect the impact of hypertension on the occurrence of cardiovascular events. Landmark studies 2, 3 demonstrated that an activated renin-angiotensin-aldosterone system (RAAS) is associated with an increased risk of coronary and cerebrovascular events independent of blood pressure levels and substantial evidence has subsequently linked pharmacological inhibition of the RAAS with effective cardiovascular 4 and renal 5 protection in hypertensive patients. In addition to its pressor effects, the RAAS has been associated with a variety of nonhemodynamic actions that might contribute to the progression of cardiovascular and renal pathology. 6 Many clinically relevant cardiovascular events in hypertensive patients are usually due to formation of a thrombus at the site of an atherosclerotic plaque. 7 Moreover, the hemostatic system is directly involved in the atherosclerotic process 8 and a prothrombotic state affects the impact of hypertension on the development of organ damage 9 and thereby on cardiovascular morbidity. 10, 11 Strong evidence that has been obtained both in animal and human studies supports an interaction between the RAAS and the coagulation and fibrinolytic systems (reviewed in ref. [12] [13] [14] . In hypertension, the link between the RAAS and the coagulation-fibrinolytic system is indirectly supported by the findings of a series of elegant studies conducted with RAAS blockers. [15] [16] [17] [18] [19] [20] [21] [22] We have hypothesized that an increased activity of the RAAS is associated with a prothrombotic state and thereby contribute to the development of organ damage in essential hypertension. To test this hypothesis, we have measured components of the RAAS and parameters that directly assess the activation of coagulation and fibrinolysis in a large group of hypertensive patients in whom the extent of organ damage has been characterized. 
Patients.
Overall, 247 patients (age: 53 ± 11 years; 128 men and 119 women) with arterial hypertension who were referred to our hypertension clinic were included in a cross-sectional study. Blood pressure was measured using a mercury sphygmomanometer according to current guidelines, and diagnosis of hypertension was established by standard criteria. 23 The patients seen at our clinic are white, include individuals with all grades of hypertension living in northeast Italy, and are representative of hypertensive patients in this geographic area. 24 The patients were either referred to us by their family physicians or presented spontaneously to our outpatient service. History and medical records were used to estimate duration of hypertensive disease (this ranged from 3 months to 25 years). Exclusion criteria were age >75 years; all secondary forms of hypertension; diabetes mellitus; pregnancy; severe obesity; renal failure with creatinine clearance <30 ml/min/1.73 m 2 of body surface area; urinary protein excretion >3.0 g/day; presence of hemostatic disorders or treatment with warfarin; and presence of other diseases or treatments that might interfere with the RAS or the coagulation system. Patients with a BMI of ≥35, 25 diabetes, 26 and advanced renal failure 27 were excluded because these conditions are known to affect both the RAAS and hemostatic variables. We also excluded hypertensive patients with acute illness and recent (<6 months) myocardial infarction, unstable angina, or stroke. None of the patients included in the study had received drug-eluting stents for coronary heart disease in the past 2 years. The number of patients was planned to give a power of >95% in detecting a 15% difference between patients with and without evidence of cardiovascular damage with an α-value of 0.05. Secondary causes of hypertension were excluded on the basis of extensive laboratory testing. Hypertension-related organ damage was assessed in all patients by history, clinical examination, and laboratory tests including measurements of 24-h creatinine clearance, 24-h proteinuria, electrocardiography, echocardiography, and ultrasound examination of aorta, carotid, iliac, and femoral arteries as performed in previous studies to which readers are referred for further details. 28, 29 Additional laboratory tests, including treadmill exercise testing, myocardial perfusion scan, and coronary, cerebral, and iliac-femoral angiography were performed when appropriate. The retrospective diagnosis of myocardial infarction was confirmed by documented history, electrocardiographic changes, and greater than twofold elevation of the serum creatinine kinase with positive muscle-brain fraction. The neurological diagnosis of transient ischemic attack and stroke was confirmed by documented history, clinical signs, and computerized cerebral axial tomography. The assessment of the cardiovascular status was performed without prior knowledge of patients' biochemical parameters.
One-hundred-sixty-three (66%) of the hypertensive patients were taking antihypertensive drugs (monotherapy, 42%; multiple-drug therapy, 58%; angiotensin-converting enzyme inhibitors, 46%; calcium antagonists, 44%; diuretics, 39%; β-blockers, 33%; angiotensin-receptor antagonists, 14%; α-blockers, 5%), antiplatelet drugs (18%), or lipid-lowering drugs (24%) and were withdrawn from all these treatments a minimum of 3 weeks before measurement of blood parameters. Depending upon the type of drugs, withdrawal was longer (up to 5 weeks for RAAS blockers and statins). Measurements of hemostatic parameters before and after withdrawal of any antihypertensive drugs did not reveal significant changes. At the time of the study, patients were requested to eat a standard diet for 7 days to maintain a sodium intake of ~100-150 mmol/day. This was verified by 24-h urine collections. The protocol received approval by the local ethics committee.
Laboratory measurements. A sample of venous blood was obtained between 8:00 and 8:30 am without venous stasis, after fasting for 12-14 h and after the patients had been in the sitting position for 10 min. The blood was collected into silicone-treated glass tubes where it was mixed with 10% of its volume of 0.1 mol/l trisodium citrate and immediately centrifuged at 1,700g for 20 min at 4 °C. The plasma was frozen at −80 °C until assayed. Total, LDL, and HDL cholesterol and triglycerides were assayed enzymatically by an automated method. 28 Plasma fibrinogen, d-dimer, prothrombin fragment 1+2, and antithrombin III were determined as previously described. 9 Plasminogen activator inhibitor-1 (PAI-1) was assayed by enzyme immunoassay (Innotest PAI-1; BykSangtec, Dietzenbach, Germany) as previously described. 30 Inter-and intraassay coefficients of variation for fibrinogen, d-dimer, fragment 1+2, antithrombin III, and PAI-1 were <8%. Plasma renin activity (PRA) and plasma aldosterone concentrations were measured using radioimmunoassay according to current guidelines 31 in plasma samples obtained with patients in the sitting position, as previously described. 32 Both PRA and aldosterone values were referred to the urinary sodium excretion of a 24-h collection completed on the day of sampling. 31 Angiotensin-converting enzyme activity was measured using a colorimetric assay.
Statistical analysis.
All values are expressed as mean ± s.d. Normality of distribution was assessed by the KolmogorovSmirnov test, and variables with skewed distribution were analyzed after logarithmic transformation. The Student's t-test was used for comparisons between two groups, and ANOVA was used for comparisons of more than two groups. Pearson's χ 2 -test was used to compare frequency distributions. Relationship between continuously distributed variables was examined by linear regression analysis, and the correlation was expressed by the Pearson's correlation coefficient. Multiple regression analysis was used to ascertain which variables were independently correlated. Stepwise multiple discriminant analysis was performed to ascertain the independence of association of variables with hypertensive organ damage. Two-tailed probability values <0.05 were considered to indicate statistical significance.
reSultS Table 1 summarizes the clinical characteristics and the metabolic, hormonal, and coagulation measurements of the study articles Renin and Prothrombotic State patients with the intergroup comparison of patients with different PRA levels. Increasing PRA concentrations were associated with higher diastolic blood pressure values and higher plasma potassium and aldosterone concentrations. Significant association with increasing PRA was also demonstrated for plasma fibrinogen, d-dimer, and PAI-1 concentrations. No significant difference in PRA, fibrinogen, d-dimer, and PAI-1 levels was observed between hypertensive patients who, before inclusion, were taking antihypertensive drugs and nevertreated patients. Separate analysis of treatment-naive patients showed a borderline statistical significance among PRA tertiles only for PAI-1 levels ( Table 2) .
Univariate analysis showed that log PRA levels were directly correlated with log fibrinogen (r = 0.403; P < 0.001), articles Renin and Prothrombotic State log d-dimer (r = 0.339; P < 0.001), and log PAI-1 (r = 0.456; P < 0.001) levels (Figure 1) . Log PRA was also positively correlated with diastolic blood pressure (r = 0.168; P = 0.020) and log plasma aldosterone (r = 0.492; P < 0.001) levels. Log aldosterone was positively correlated with log fibrinogen (r = 0.283; P < 0.001), log d-dimer (r = 0.227; P < 0.001), and log PAI-1 (r = 0.325; P < 0.001) levels. No correlations of plasma angiotensin-converting enzyme and urinary electrolyte excretion with coagulation parameters were observed. Multiple regression analysis was performed with a forward stepwise approach in which variables that were significantly related to log PRA in univariate analysis were included following the strength of the relationship. Analysis showed that log PRA was independently related with log aldosterone (β = 0.276; P < 0.001), log PAI-1 (β = 0.172; P = 0.007), and log fibrinogen (β = 0.153; P = 0.016). Correlation of log aldosterone with log fibrinogen and log PAI-1 was eliminated by inclusion of log PRA. Clinical and/or laboratory evidence of hypertension-related organ damage was found in 136 of 247 hypertensive patients (55%). Cardiac disease was found in 71 (29%) hypertensive patients (left ventricular hypertrophy, 25%; angina pectoris, 6%; myocardial infarction, 4%; heart failure, 4%); renal disease was detected in 74 (30%) patients (microalbuminuria, 29%; impaired glomerular filtration, 15%); cerebrovascular disease was detected in 39 (16%) patients (ultrasound evidence of carotid plaques, 15%; transient ischemic attack, 3%; stroke, 2%); peripheral vascular disease was present in 12 (5%) patients (claudicatio, 4%; aortic or other site aneurysm, 2%). All types of organ damage resulted to be more frequent (all P < 0.01) in patients who were previously treated with antihypertensive drugs as compared to naive patients, and this was related principally to the longer duration of hypertension. The clinical, metabolic, hormonal, and coagulation measurements of hypertensive subjects with and without evidence of organ damage are shown in Table 3 . PRA and plasma aldosterone, fibrinogen, d-dimer, fragment 1+2, and PAI-1 levels were significantly greater among hypertensive patients with clinical or instrumental evidence of organ damage than among patients without organ damage. Additional variables that were associated with presence of organ damage were age, blood pressure levels, duration of hypertension, smoking status, and lower HDL cholesterol levels. Multivariate discriminant analysis was performed to evaluate further the articles Renin and Prothrombotic State association of these factors with hypertensive organ damage. This analysis indicated that blood pressure (P < 0.001), age (P = 0.012), smoking status (P = 0.018), and log PRA (P = 0.023) are independently associated with organ damage.
Inclusion of log PRA in the multivariate model excluded log aldosterone as an independent predictor of organ damage. Also, log fibrinogen (P = 0.014) and log PAI-1 (P = 0.009) levels had independent association with organ damage and their inclusion in the stepwise model eliminated PRA as an independent predictor.
We further analyzed the association of RAAS parameters and hemostatic variables with different types of organ damage. This analysis indicated that elevated PRA, fibrinogen, and PAI-1 levels were independently associated with the presence of cardiac and renal, but not cerebrovascular, disease ( Table 4) .
diScuSSion
This study demonstrates a highly significant relationship of PRA and plasma aldosterone with markers of activated coagulation and decreased fibrinolytic activity in patients with essential hypertension. Elevated plasma levels of PRA, aldosterone, and prothrombotic markers are associated with clinical and instrumental evidence of cardiac and renal hypertensive organ damage, and multivariate discriminant analysis indicates that the prothrombotic state might contribute to the relationship between an activated RAAS and occurrence of such damage.
Many studies have been conducted to assess the function of the hemostatic system in patients with hypertension. Increased platelet activation, increased activity of the coagulation system, and decreased function of the fibrinolytic system have been consistently reported in comparison to normotensive subjects, which suggests the existence of a prothrombotic state related to hypertension 10, 11 that could contribute to development of organ damage. 9 Substantial evidence demonstrates an interaction between the RAAS and fibrinolytic system, 12-14 and a relationship of PRA and plasma aldosterone with PAI-1 levels has been reported in patients with essential hypertension. 33 This study expands this relationship of PRA and aldosterone to additional hemostatic markers, such as fibrinogen and d-dimer, a reliable tracer of the overall state of activation of the coagulation system, suggesting that, in addition to decreasing the fibrinolytic activity, the RAAS might activate coagulation. Thus, in hypertensive patients, an activated RAAS is associated with a shift in the balance between procoagulant and anticoagulant factors into the direction of the former, thereby leading to a prothrombotic state that could contribute to occurrence of cardiovascular events. One possible link between the RAAS and the hemostatic system is thought to be via the endothelium. Binding of angiotensin II to endothelial cells results in many functional abnormalities of these cells, including dose-dependent PAI-1 release, 34 and it is well established that endothelial dysfunction anticipates both cardiac and renal hypertensive complications. In addition, experiments that were conducted in rats with genetic hypertension demonstrated that the RAAS plays a pivotal role in the development of thrombotic microangiopathy and subsequent organ damage. 35 This damage is thought to be the consequence of endothelial dysfunction 36 and occurs independent of blood pressure levels. 35 Previous studies have attempted to define the relative weights of renin and aldosterone in the induction of the prothrombotic state. In our study, correlations of PRA with all prothrombotic markers were stronger than those observed for plasma aldosterone, and multivariate analysis indicated that PRA remained significantly correlated with both fibrinogen and PAI-1 after inclusion of aldosterone in the stepwise model. Conversely, inclusion of PRA in the model eliminated the correlation of aldosterone with all prothrombotic markers, suggesting a predominant role of renin in the relationship of the RAAS with the hemostatic system. The results of this analysis should be interpreted with caution because the interrelationship of all these factors make it difficult to define the relative contributions of renin and aldosterone to the prothrombotic state. Also, it must be noticed that studies conducted in vitro demonstrated that angiotensin II and aldosterone interact synergistically to increase PAI-1 release, 37 and Sawathiparnich et al. 38 showed that use of spironolactone in hypertensive patients prevents the increase in PAI-1 levels, supporting the possibility that aldosterone is an independent contributor to PAI-1 levels. Consistent with the latter observation, it has been recently shown that, in stroke-prone spontaneously hypertensive rats, aldosterone is more potent than angiotensin II in the induction of renal profibrotic factors, including PAI-1. 39 An increasing body of literature has indicated that fibrinogen, d-dimer, and PAI-1 are independent risk factors for major cardiovascular events in the general population and hypertensive subjects 40 and that an activated RAAS is associated with an increased coronary and cerebrovascular risk independent of blood pressure levels. 2, 3 This study is the first to examine the relevance of the interaction between the RAAS and a prothrombotic state on the presence of organ damage in patients with essential hypertension. We have observed that an activated RAAS and elevated levels of fibrinogen, d-dimer, and PAI-1 are associated with the presence of hypertensive organ damage as defined by extensive clinical, biochemical, and instrumental diagnostic work-up. Separate analysis of patients with different types of damage indicates that elevated PRA, fibrinogen, and PAI-1 are associated with the presence of cardiac and renal involvement. In a multivariate analysis, both fibrinogen and PAI-1 resulted to be independently associated with organ damage and their inclusion in a stepwise model eliminated PRA and aldosterone as independent predictors. This suggests that the impact of an activated RAAS on hypertensive organ damage might be mediated by the prothrombotic state.
The main limitation of this study is due to the cross-sectional design that does not clearly permit to establish evidence of a causal relationship between elevated PRA and aldosterone, prothrombotic state, and hypertensive organ damage. However, the statistical strength of these relationships and the independent association demonstrated by multivariate analysis strongly suggest the possibility of a functional link. In addition, in this study, cardiovascular end points were determined retrospectively and in ad hoc manner; this may have introduced ascertainment bias. Finally, inclusion of both treatmentnaive patients and patients who had been already treated with antihypertensive agents could have caused some differences in the hemostatic variables. In this study, however, these variables did not differ between treatment-naive and previously treated patients and, among the latter, no significant differences were found in measurements obtained before and after drug withdrawal.
Reversal of functional abnormalities of target organs and prevention of major cardiovascular events are primary goals of treatment in hypertensive patients. It is increasingly clear that essential hypertension is associated with a prothrombotic state. This study suggests that an activated RAAS might contribute to the hypercoagulable state, inasmuch as both PRA and plasma aldosterone are significantly and independently related with markers that are indicative of activated coagulation and impaired fibrinolytic pathways. This study demonstrates also that the interaction between the RAAS and the hemostatic system could play a role in the occurrence of hypertensive organ damage. The present findings might suggest potential benefits of pharmacological modulation of the hemostatic pathways in preventing hypertensive organ damage. Future studies will have to address this hypothesis. 
